Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05747716
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-02-28
First Post:
2023-02-18
Brief Title:
SBRT Combined With Fruquintinib Plus PD-1CTLA-4 Antibody for Third-line Treatment in mCRC
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
SBRT Combined With Fruquintinib Plus PD-1CTLA-4 Antibody Cadonilimab for Third-line Treatment in Metastatic Colonrectal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a phase II clinical study The purpose of the study is to evaluate the efficacy and safety of SBRT combined with Fruquintinib Plus PD-1CTLA-4 Antibody for Third-line Treatment in mCRC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None